Table 2.

Clinical trials of PLA₂ inhibitors.

Inhibitor	Clinical trial	Condition
Varespladib (sPLA2)	Phase III clinical trial VISTA-16 clinicaltrials.gov Identifier: NCT01130246	Acute coronary syndrome
Giripladib (cPLA2)	Phase II clinical trial clinicaltrials.gov Identifier: NCT00396955	Osteoarthritis
	Phase I clinical trial clinicaltrials.gov Identifier: NCT00440492	Rheumatoid arthritis
PF-5212372 (ZPL-5212372) (cPLA2)	Phase I/II study clinicaltrials.gov Identifier: NCT02795832	Atopic dermatitis
Darabladib (LpPLA2)	Phase III clinical trial STABILITY clinicaltrials.gov Identifier: NCT00799903	Atherosclerosis
	Phase III clinical trial SOLID-TIMI 52 clinicaltrials.gov Identifier: NCT01000727	Acute coronary syndrome
	Phase III clinical trial clinicaltrials.gov Identifier:NCT01067339	Endothelial dysfunction/ Coronary atherosclerosis
	Phase II clinical trial clinicaltrials.gov Identifier:NCT01506895	Diabetic retinopathy
Rilapladib (LpPLA2)	Phase II clinical trial clinicaltrials.gov Identifier: NCT01428453	Alzheimer's disease
	Phase II clinical trial clinicaltrials.gov Identifier: NCT00695305	Atherosclerosis
GSK2647544 (LpPLA2)	Phase I clinical trial clinicaltrials.gov Identifier: NCT01702467, NCT01978327, NCT01924858	Alzheimer's disease